Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE000D8XC064
| Stock Name / Fund | iShares World Equity Enhanced Active UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WOEE(GBP) LSE |
| ETF Ticker | WOEE.AS(USD) AS |
| ETF Ticker | WOEE.AS(USD) Euronext Amsterdam |
Holdings detail for ASND
| Stock Name | Ascendis Pharma AS |
| Ticker | ASND(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US04351P1012 |
| LEI | 549300B66JN3W3J8GH73 |
Show aggregate ASND holdings
News associated with ASND
- Ascendis Pharma A/S (NASDAQ:ASND) Receives $244.36 Average PT from Analysts
- Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have been given a consensus rating of “Buy” by the fifteen analysts that are covering the stock, Marketbeat Ratings reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on […] - 2025-09-19 02:58:53
- Ascendis Pharma A/S (NASDAQ:ASND) Cut to “Hold” at Wall Street Zen
- Wall Street Zen lowered shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) from a buy rating to a hold rating in a report issued on Friday morning. A number of other brokerages have also recently issued reports on ASND. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from […] - 2025-09-08 02:54:56
- Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High Following Analyst Upgrade
- Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) shares reached a new 52-week high during trading on Tuesday after Bank of America raised their price target on the stock from $227.00 to $230.00. Bank of America currently has a buy rating on the stock. Ascendis Pharma A/S traded as high as $202.79 and last traded […] - 2025-09-04 02:20:48
- Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target upped by JPMorgan Chase & Co. from $254.00 to $260.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. A number of other research firms also recently commented on ASND. UBS Group reaffirmed […] - 2025-08-20 03:10:54
- Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High After Analyst Upgrade
- Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) shares reached a new 52-week high during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $199.99 and last traded at $193.57, with a volume of 1554046 shares changing hands. The stock […] - 2025-08-13 02:17:08
- Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective increased by Royal Bank Of Canada from $210.00 to $230.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on ASND. UBS […] - 2025-08-11 03:58:55
- Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $254.00
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price raised by Stifel Nicolaus from $212.00 to $254.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other brokerages have also issued reports on ASND. Royal Bank Of Canada boosted their price […] - 2025-08-11 03:58:52
- Ascendis Pharma A/S (NASDAQ:ASND) Given New $307.00 Price Target at UBS Group
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective lifted by UBS Group from $306.00 to $307.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. […] - 2025-08-11 03:58:52
- Wedbush Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective boosted by Wedbush from $212.00 to $220.00 in a research note issued to investors on Friday,Benzinga reports. Wedbush currently has an outperform rating on the biotechnology company’s stock. A number of other research analysts also recently commented on the stock. Evercore ISI boosted their […] - 2025-08-11 03:58:51
- Ascendis Pharma A/S (NASDAQ:ASND) Raised to Buy at Wall Street Zen
- Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. ASND has been the topic of several other reports. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S […] - 2025-08-11 03:58:51
- Citigroup Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price hoisted by Citigroup from $243.00 to $290.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. ASND has been the topic of several other reports. Stifel Nicolaus raised their target price on shares […] - 2025-08-11 03:58:51
- CGGR's Underlying Holdings Imply 10% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:36
- XTX Topco Ltd Buys New Shares in Ascendis Pharma A/S (NASDAQ:ASND)
- XTX Topco Ltd bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,746 shares of the biotechnology company’s stock, valued at approximately $584,000. Several other institutional investors and hedge […] - 2025-08-06 05:20:59
- Ascendis Pharma A/S (NASDAQ:ASND) Receives $223.07 Average PT from Analysts
- Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned an average recommendation of “Buy” from the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Fifteen analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last […] - 2025-07-31 03:13:06
- Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $254.00 at JPMorgan Chase & Co.
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target increased by JPMorgan Chase & Co. from $245.00 to $254.00 in a research note released on Tuesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. ASND has been the subject of a number of other research reports. Cantor Fitzgerald reiterated […] - 2025-07-30 04:34:56
- Ascendis Pharma Says FDA Approves SKYTROFA For Adults With Growth Hormone Deficiency
- (RTTNews) - Swiss biopharmaceutical company Ascendis Pharma A/S (ASND) announced Monday that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth - 2025-07-28 08:40:00
- Victory Capital Management Inc. Cuts Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
- Victory Capital Management Inc. lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 4.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,926 shares of the biotechnology company’s stock after selling 6,427 shares during the […] - 2025-07-23 06:00:57
- Sigma Planning Corp Purchases Shares of 1,515 Ascendis Pharma A/S (NASDAQ:ASND)
- Sigma Planning Corp bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,515 shares of the biotechnology company’s stock, valued at approximately $236,000. A […] - 2025-07-22 07:24:51
- Morgan Stanley Initiates Coverage on Ascendis Pharma A/S (NASDAQ:ASND)
- Morgan Stanley began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $250.00 price target on the biotechnology company’s stock. A number of other analysts have also recently issued reports on ASND. Wedbush boosted their […] - 2025-07-04 04:59:43
- Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $224.00
- Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price hoisted by Oppenheimer from $215.00 to $224.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. ASND has been the topic of several other reports. Bank of America increased their target […] - 2025-06-16 02:50:47
- Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $216.73
- Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned an average rating of “Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Fifteen equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in […] - 2025-06-11 04:54:50
- Bank of America Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock
- Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price target hoisted by Bank of America from $201.00 to $216.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price target suggests a potential upside of 25.33% from the company’s current […] - 2025-06-11 02:44:49
- Two Sigma Investments LP Cuts Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
- Two Sigma Investments LP decreased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 78.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,915 shares of the biotechnology company’s stock after selling 39,173 shares during the period. Two Sigma Investments LP’s holdings in Ascendis Pharma A/S were worth $1,503,000 […] - 2025-06-04 05:08:54
- Nuveen Asset Management LLC Sells 170 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
- Nuveen Asset Management LLC lessened its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 1.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,430 shares of the biotechnology company’s stock after selling 170 shares during the period. Nuveen Asset Management LLC’s holdings in Ascendis Pharma A/S were worth $1,987,000 as of […] - 2025-06-04 04:36:50
- Two Sigma Advisers LP Has $743,000 Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
- Two Sigma Advisers LP cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 88.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,400 shares of the biotechnology company’s stock after selling 41,858 shares during the quarter. Two Sigma Advisers […] - 2025-06-03 05:00:51
- ProShare Advisors LLC Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
- ProShare Advisors LLC reduced its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 16.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,857 shares of the biotechnology company’s stock after selling 567 shares during the quarter. ProShare Advisors […] - 2025-05-28 04:54:54
- Tower Research Capital LLC TRC Boosts Stake in Ascendis Pharma A/S (NASDAQ:ASND)
- Tower Research Capital LLC TRC grew its position in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 195.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,004 shares of the biotechnology company’s stock after purchasing an additional 664 shares during the period. Tower Research Capital […] - 2025-05-08 05:08:53
- Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Morgan Stanley
- Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, MarketBeat reports. The firm presently has a $250.00 price objective on the biotechnology company’s stock, up from their previous price objective […] - 2025-05-07 02:58:50
- LPL Financial LLC Increases Position in Ascendis Pharma A/S (NASDAQ:ASND)
- LPL Financial LLC increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 60.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,199 shares of the biotechnology company’s stock after acquiring an additional 1,577 shares […] - 2025-04-24 04:54:46
- Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $204.67
- Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month […] - 2025-04-22 03:04:57
iShares World Equity Enhanced Active UCITS ETF USD (Acc) ASND holdings
| Date | Number of ASND Shares Held | Base Market Value of ASND Shares | Local Market Value of ASND Shares | Change in ASND Shares Held | Change in ASND Base Value | Current Price per ASND Share Held | Previous Price per ASND Share Held |
|---|
| 2025-11-13 (Thursday) | 635 | USD 131,096 | USD 131,096 | | | | |
| 2025-11-12 (Wednesday) | 445 | USD 88,653 | USD 88,653 | 0 | USD -863 | USD 199.22 | USD 201.16 |
| 2025-11-11 (Tuesday) | 445 | USD 89,516 | USD 89,516 | 0 | USD 2,292 | USD 201.16 | USD 196.009 |
| 2025-11-10 (Monday) | 445 | USD 87,224 | USD 87,224 | 0 | USD -770 | USD 196.009 | USD 197.739 |
| 2025-11-07 (Friday) | 445 | USD 87,994 | USD 87,994 | 0 | USD -686 | USD 197.739 | USD 199.281 |
| 2025-11-06 (Thursday) | 445 | USD 88,680 | USD 88,680 | 159 | USD 32,123 | USD 199.281 | USD 197.752 |
| 2025-11-05 (Wednesday) | 286 | USD 56,557 | USD 56,557 | 0 | USD -3,000 | USD 197.752 | USD 208.241 |
| 2025-11-04 (Tuesday) | 286 | USD 59,557 | USD 59,557 | 0 | USD 2,077 | USD 208.241 | USD 200.979 |
| 2025-11-03 (Monday) | 286 | USD 57,480 | USD 57,480 | 0 | USD -178 | USD 200.979 | USD 201.601 |
| 2025-10-31 (Friday) | 286 | USD 57,658 | USD 57,658 | 0 | USD -603 | USD 201.601 | USD 203.71 |
| 2025-10-30 (Thursday) | 286 | USD 58,261 | USD 58,261 | 0 | USD -572 | USD 203.71 | USD 205.71 |
| 2025-10-29 (Wednesday) | 286 | USD 58,833 | USD 58,833 | 0 | USD -57 | USD 205.71 | USD 205.909 |
| 2025-10-28 (Tuesday) | 286 | USD 58,890 | USD 58,890 | 128 | USD 26,780 | USD 205.909 | USD 203.228 |
| 2025-10-27 (Monday) | 158 | USD 32,110 | USD 32,110 | 0 | USD 194 | USD 203.228 | USD 202 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ASND by Blackrock for IE000D8XC064
Show aggregate share trades of ASND| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-06 | BUY | 159 | 200.550 | 196.950 | 197.310 | USD 31,372 | 203.24 |
| 2025-10-28 | BUY | 128 | 205.910 | 206.920 | 206.819 | USD 26,473 | 202.61 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ASND
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 121,748 | 6,400 | 179,053 | 68.0% |
| 2025-09-18 | 35,114 | 0 | 59,068 | 59.4% |
| 2025-09-17 | 58,718 | 10 | 109,051 | 53.8% |
| 2025-09-16 | 50,547 | 0 | 103,264 | 48.9% |
| 2025-09-15 | 45,485 | 0 | 81,865 | 55.6% |
| 2025-09-12 | 49,729 | 0 | 102,985 | 48.3% |
| 2025-09-11 | 64,066 | 0 | 158,849 | 40.3% |
| 2025-09-10 | 58,788 | 0 | 242,952 | 24.2% |
| 2025-09-09 | 38,790 | 0 | 119,195 | 32.5% |
| 2025-09-08 | 110,464 | 11 | 192,296 | 57.4% |
| 2025-09-05 | 128,647 | 6,400 | 268,849 | 47.9% |
| 2025-09-04 | 50,558 | 0 | 123,304 | 41.0% |
| 2025-09-03 | 57,923 | 2,277 | 189,313 | 30.6% |
| 2025-09-02 | 85,172 | 0 | 241,590 | 35.3% |
| 2025-08-29 | 56,548 | 3,456 | 129,201 | 43.8% |
| 2025-08-28 | 49,022 | 0 | 179,374 | 27.3% |
| 2025-08-27 | 51,035 | 0 | 170,324 | 30.0% |
| 2025-08-26 | 28,659 | 0 | 87,205 | 32.9% |
| 2025-08-25 | 55,738 | 0 | 143,979 | 38.7% |
| 2025-08-22 | 66,448 | 0 | 157,164 | 42.3% |
| 2025-08-21 | 53,383 | 0 | 178,303 | 29.9% |
| 2025-08-20 | 47,592 | 0 | 174,277 | 27.3% |
| 2025-08-19 | 50,748 | 0 | 165,115 | 30.7% |
| 2025-08-18 | 44,303 | 0 | 370,345 | 12.0% |
| 2025-08-15 | 51,406 | 0 | 101,097 | 50.8% |
| 2025-08-14 | 58,744 | 0 | 173,228 | 33.9% |
| 2025-08-13 | 86,518 | 5,446 | 289,310 | 29.9% |
| 2025-08-12 | 331,120 | 0 | 451,980 | 73.3% |
| 2025-08-11 | 115,577 | 31 | 200,963 | 57.5% |
| 2025-08-08 | 379,312 | 762 | 747,420 | 50.7% |
| 2025-08-07 | 189,347 | 0 | 343,785 | 55.1% |
| 2025-08-06 | 87,885 | 0 | 162,647 | 54.0% |
| 2025-08-05 | 129,631 | 0 | 283,397 | 45.7% |
| 2025-08-04 | 121,053 | 0 | 196,498 | 61.6% |
| 2025-08-01 | 57,635 | 0 | 106,208 | 54.3% |
| 2025-07-31 | 164,688 | 0 | 285,489 | 57.7% |
| 2025-07-30 | 105,105 | 0 | 211,067 | 49.8% |
| 2025-07-29 | 73,869 | 0 | 140,327 | 52.6% |
| 2025-07-28 | 81,940 | 0 | 148,590 | 55.1% |
| 2025-07-25 | 119,180 | 0 | 197,342 | 60.4% |
| 2025-07-24 | 113,114 | 0 | 262,843 | 43.0% |
| 2025-07-23 | 124,992 | 0 | 236,110 | 52.9% |
| 2025-07-22 | 53,127 | 0 | 112,666 | 47.2% |
| 2025-07-21 | 86,388 | 0 | 116,122 | 74.4% |
| 2025-07-18 | 183,720 | 0 | 311,132 | 59.0% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.